Cargando…
Human dosimetry of free (211)At and meta-[(211)At]astatobenzylguanidine ((211)At-MABG) estimated using preclinical biodistribution from normal mice
BACKGROUND: (211)At is one of the ideal nuclides for targeted radionuclide therapies (TRTs). Meta-[(211)At]astatobenzylguanidine ((211)At-MABG) has been proposed for the treatment of pheochromocytoma. To effectively use these radiopharmaceuticals, dosimetry must be performed. It is important to dete...
Autores principales: | Ukon, Naoyuki, Zhao, Songji, Washiyama, Kohshin, Oriuchi, Noboru, Tan, Chengbo, Shimoyama, Saki, Aoki, Miho, Kubo, Hitoshi, Takahashi, Kazuhiro, Ito, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509022/ https://www.ncbi.nlm.nih.gov/pubmed/32960387 http://dx.doi.org/10.1186/s40658-020-00326-7 |
Ejemplares similares
-
Preclinical Development of [(211)At]meta- astatobenzylguanidine ([(211)At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
por: Batra, Vandana, et al.
Publicado: (2022) -
Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody
por: Oriuchi, Noboru, et al.
Publicado: (2020) -
OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020) -
Simulation of the distribution of astatine-211 solution dispersion in a lab room
por: Kubo, Hitoshi, et al.
Publicado: (2021) -
Manual on the proper use of meta-[(211)At] astato-benzylguanidine ([(211)At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)
por: Ukon, Naoyuki, et al.
Publicado: (2022)